FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910180894> ?p ?o ?g. }

• W2910180894 endingPage "205521731882461" @default.
• W2910180894 startingPage "205521731882461" @default.
• W2910180894 abstract "Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies.To assess the efficacy of teriflunomide following natalizumab discontinuance in relapsing multiple sclerosis patients.Clinically stable relapsing multiple sclerosis patients completing 12 or more consecutive months of natalizumab, testing positive for anti-John Cunningham virus antibody, started teriflunomide 14 mg/day, 28 ± 7 days after their final natalizumab infusion. Physical examination, Expanded Disability Status Scale, laboratory assessments, and brain magnetic resonance imaging were performed at screening and multiple follow-up visits.Fifty-five patients were enrolled in the study. The proportion of patients relapse-free was 0.94, restricted mean time to first gadolinium-enhancing lesion was 10.9 months and time to 3-month sustained disability worsening was 11.8 months. The mean number of new or enlarging T2 lesions per patient at 12 months was 0.42. Exploratory analyses revealed an annualized relapse rate of 0.08, and a proportion of patients with no evidence of disease activity of 0.68. Forty-seven patients (85.5%) reported adverse events, 95% of which were mild to moderate.Teriflunomide therapy initiated without natalizumab washout resulted in a low rate of return of disease activity. Clinicians may consider this a worthwhile strategy when transitioning clinically stable patients off natalizumab to another therapy.ClinicalTrials.gov Identifier: NCT01970410." @default.
• W2910180894 created "2019-01-25" @default.
• W2910180894 creator A5008348889 @default.
• W2910180894 creator A5009982790 @default.
• W2910180894 creator A5031174072 @default.
• W2910180894 creator A5031527611 @default.
• W2910180894 creator A5035582436 @default.
• W2910180894 creator A5056378169 @default.
• W2910180894 creator A5059295367 @default.
• W2910180894 creator A5060878682 @default.
• W2910180894 creator A5064338988 @default.
• W2910180894 creator A5066580511 @default.
• W2910180894 creator A5067317369 @default.
• W2910180894 creator A5067436670 @default.
• W2910180894 creator A5067690675 @default.
• W2910180894 date "2019-01-01" @default.
• W2910180894 modified "2023-09-28" @default.
• W2910180894 title "Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy" @default.
• W2910180894 cites W1514064771 @default.
• W2910180894 cites W1867182292 @default.
• W2910180894 cites W1970758701 @default.
• W2910180894 cites W1983511886 @default.
• W2910180894 cites W1994381563 @default.
• W2910180894 cites W1997159649 @default.
• W2910180894 cites W1998000193 @default.
• W2910180894 cites W2014391919 @default.
• W2910180894 cites W2042865787 @default.
• W2910180894 cites W2043591841 @default.
• W2910180894 cites W2044022462 @default.
• W2910180894 cites W2045727999 @default.
• W2910180894 cites W2049675062 @default.
• W2910180894 cites W2082301205 @default.
• W2910180894 cites W2103758700 @default.
• W2910180894 cites W2106467284 @default.
• W2910180894 cites W2109515582 @default.
• W2910180894 cites W2123870007 @default.
• W2910180894 cites W2129586747 @default.
• W2910180894 cites W2133329597 @default.
• W2910180894 cites W2149457184 @default.
• W2910180894 cites W2153041730 @default.
• W2910180894 cites W2162469926 @default.
• W2910180894 cites W2169569625 @default.
• W2910180894 cites W2313484897 @default.
• W2910180894 cites W2317727574 @default.
• W2910180894 cites W2330356903 @default.
• W2910180894 cites W2568154480 @default.
• W2910180894 cites W2748840293 @default.
• W2910180894 cites W2756086242 @default.
• W2910180894 cites W2771372669 @default.
• W2910180894 cites W2788327628 @default.
• W2910180894 doi "https://doi.org/10.1177/2055217318824618" @default.
• W2910180894 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6350141" @default.
• W2910180894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30729028" @default.
• W2910180894 hasPublicationYear "2019" @default.
• W2910180894 type Work @default.
• W2910180894 sameAs 2910180894 @default.
• W2910180894 citedByCount "3" @default.
• W2910180894 countsByYear W29101808942021 @default.
• W2910180894 countsByYear W29101808942022 @default.
• W2910180894 crossrefType "journal-article" @default.
• W2910180894 hasAuthorship W2910180894A5008348889 @default.
• W2910180894 hasAuthorship W2910180894A5009982790 @default.
• W2910180894 hasAuthorship W2910180894A5031174072 @default.
• W2910180894 hasAuthorship W2910180894A5031527611 @default.
• W2910180894 hasAuthorship W2910180894A5035582436 @default.
• W2910180894 hasAuthorship W2910180894A5056378169 @default.
• W2910180894 hasAuthorship W2910180894A5059295367 @default.
• W2910180894 hasAuthorship W2910180894A5060878682 @default.
• W2910180894 hasAuthorship W2910180894A5064338988 @default.
• W2910180894 hasAuthorship W2910180894A5066580511 @default.
• W2910180894 hasAuthorship W2910180894A5067317369 @default.
• W2910180894 hasAuthorship W2910180894A5067436670 @default.
• W2910180894 hasAuthorship W2910180894A5067690675 @default.
• W2910180894 hasBestOaLocation W29101808941 @default.
• W2910180894 hasConcept C126322002 @default.
• W2910180894 hasConcept C1862650 @default.
• W2910180894 hasConcept C197934379 @default.
• W2910180894 hasConcept C203014093 @default.
• W2910180894 hasConcept C2776036978 @default.
• W2910180894 hasConcept C2777703276 @default.
• W2910180894 hasConcept C2780640218 @default.
• W2910180894 hasConcept C2780892749 @default.
• W2910180894 hasConcept C2781004633 @default.
• W2910180894 hasConcept C71924100 @default.
• W2910180894 hasConceptScore W2910180894C126322002 @default.
• W2910180894 hasConceptScore W2910180894C1862650 @default.
• W2910180894 hasConceptScore W2910180894C197934379 @default.
• W2910180894 hasConceptScore W2910180894C203014093 @default.
• W2910180894 hasConceptScore W2910180894C2776036978 @default.
• W2910180894 hasConceptScore W2910180894C2777703276 @default.
• W2910180894 hasConceptScore W2910180894C2780640218 @default.
• W2910180894 hasConceptScore W2910180894C2780892749 @default.
• W2910180894 hasConceptScore W2910180894C2781004633 @default.
• W2910180894 hasConceptScore W2910180894C71924100 @default.
• W2910180894 hasFunder F4320333587 @default.
• W2910180894 hasIssue "1" @default.
• W2910180894 hasLocation W29101808941 @default.
• W2910180894 hasLocation W29101808942 @default.

• next